The first AIDS vaccine trial in Africa has been launched in Uganda, announced the National Institute of Allergy and Infectious Diseases (NIAID), which is sponsoring the phase 1 study.
The HIV vaccine involved in the trial uses three HIV genes inserted into a weakened version of the canarypox virus. This vaccine has already undergone safety testing in about 800 people in the United States and France, with no serious adverse effects reported.
The study, which will last for about a year, will enroll 40 healthy HIV-negative adults, who will be randomly assigned to receive four injections of the vaccine, a canarypox rabies vaccine, or a placebo. Researchers will continue to monitor safety and durability of immune responses to the vaccine for an additional year.
Stephenson J. AIDS Vaccine Trial. JAMA. 1999;281(11):978. doi:10.1001/jama.281.11.978-JHA90001-2-1